EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes

Thomas J Wilkinson iD, Jonathan Goldney, Thomas Yates, Joseph Henson, Francesco Zaccardi, Kamlesh Khunti, David Webb, Dimitris Papamargaritis iD, Melanie J Davies

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfaf258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Thomas J Wilkinson und 8 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre, Leicester, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Weight Loss, Renal Insufficiency, Chronic, Bariatric Surgery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Leicester Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large, high-quality, real-world studies on the efficacy of weight-lowering interventions, including the glucagon-like peptide-1–based therapies semaglutide and tirzepatide, as well as bariatric surgery (BS). This retrospective cohort study evaluates these interventions on cardiorenal outcomes and mortality using health records from TriNetX US Collaborative Network.

Methods

Three cohorts with T2DM and CKD living with overweight or obesity, prescribed semaglutide or tirzepatide, or with a BS procedure were propensity-score matched with a cohort receiving dipeptidyl peptidase 4 inhibitors (DPP4i, weight-neutral control). We investigated the hazard ratio (HR) of: (i) end-stage renal disease (ESRD); (ii) myocardial infarction (MI); (iii) stroke; and (iv) all-cause mortality.

Results

Cohorts included 17 749 (semaglutide, age 64.1 ± 10.9 years, 57.4% female), 4211 (tirzepatide, 63.7 ± 10.8, 58.1%) and 2603 (BS, 56.1 ± 11.2, 74.1%) patients. Compared with DPP4i, semaglutide reduced the risk of ESRD [HR 0.78 (95% confidence interval 0.71 to 0.85)], while tirzepatide showed a reduction of 42% (0.0.58, 0.45 to 0.75). BS lowered ESRD risk (0.79, 0.67 to 0.92). Semaglutide reduced MI (0.80, 0.72 to 0.88) and stroke (0.85, 0.77 to 0.95) risk, while tirzepatide lowered MI and stroke by 24%. BS was associated with reduced MI (0.45, 0.35 to 0.58) and stroke (0.57, 0.44 to 0.74) risk. All-cause mortality risk was reduced by semaglutide (0.64, 0.59 to 0.70), tirzepatide (0.47, 0.35 to 0.63) and BS (0.68, 0.57 to 0.81).

Conclusions

Using a real-world dataset, semaglutide, tirzepatide and BS—interventions shown to elicit weight loss and improve glycaemic control—have a myriad of benefits on cardio-renal outcomes and mortality, supporting their use as disease-modifying therapy options in T2DM and CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Weight LossRenal Insufficiency, ChronicBariatric SurgeryObesityHumansFemaleSemaglutideRetrospective StudiesMaleTirzepatideMiddle AgedAgedGlucagon-Like PeptidesFollow-Up StudiesPrognosisGlomerular Filtration RateKidney Function TestsRisk Factors

Stichwörter der Autor:innen

bariatric surgeryobesitysemaglutidetirzepatidetype 2 diabetes

Substanzen

SemaglutideTirzepatideGlucagon-Like Peptides

Autor:innen und Institutionen

  • NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre, Leicester, UK.
  • Leicester Diabetes Centre, Leicester General Hospital, University of Leicester, Leicester, UK.
  • NIHR Applied Research Collaboration East Midlands, Leicester Diabetes Centre, Leicester, UK.
  • University of Hospitals Leicester NHS Trust, Leicester, UK.

ORCID-Profile: Thomas J Wilkinson, Dimitris Papamargaritis

Förderung

  • NIHR Leicester Biomedical Research Centre

Zitieren

APA

Wilkinson, T. J., Goldney, J., Yates, T., Henson, J., Zaccardi, F., Khunti, K., Webb, D., Papamargaritis, D., & Davies, M. J. (2026). Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf258

Vancouver

Wilkinson TJ, Goldney J, Yates T, Henson J, Zaccardi F, Khunti K, et al. Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfaf258

BibTeX
@article{Wilkinson2026,
  author = {Wilkinson, Thomas J and Goldney, Jonathan and Yates, Thomas and Henson, Joseph and Zaccardi, Francesco and Khunti, Kamlesh and Webb, David and Papamargaritis, Dimitris and Davies, Melanie J},
  title = {Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfaf258}
}
Kostenlos starten →